The study published in the American Journal of Cancer Research shows that the Food and Drug Administration-approved medication crizotinib (also known by its name brand, Xalkori) is effective at inhibiting the growth of non-small cell lung cancer with the most common genetic mutations.
Existing Drug Shows Promise in Treating Most Prevalent Type of Lung Cancer miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Two University of Kentucky researchers in the College of Pharmacy have been named fellows of the National Academy of Inventors (NAI). Linda Dwoskin, Ph.D., and Chang-Guo Zhan, Ph.D., have earned the highest professional distinction given to academic inventors.